Maze Therapeutics (NASDAQ:MAZE) Posts Quarterly Earnings Results, Hits Expectations

Maze Therapeutics (NASDAQ:MAZE) issued its quarterly earnings data on Tuesday. The company reported ($0.76) earnings per share for the quarter, hitting the consensus estimate of ($0.76), Zacks reports.

Maze Therapeutics Price Performance

NASDAQ MAZE traded up $0.44 during trading hours on Thursday, reaching $27.97. 101,377 shares of the stock traded hands, compared to its average volume of 663,918. The company has a market cap of $1.55 billion, a price-to-earnings ratio of -11.08 and a beta of 2.21. The stock has a 50 day simple moving average of $27.69 and a two-hundred day simple moving average of $33.19. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.88 and a quick ratio of 17.88. Maze Therapeutics has a 1 year low of $12.81 and a 1 year high of $53.65.

Insider Activity at Maze Therapeutics

In other news, insider Atul Dandekar sold 7,500 shares of the stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $27.34, for a total value of $205,050.00. Following the sale, the insider directly owned 26,250 shares of the company’s stock, valued at approximately $717,675. This represents a 22.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 14,609 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $29.90, for a total value of $436,809.10. Following the sale, the chief marketing officer directly owned 14,609 shares in the company, valued at $436,809.10. This trade represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 126,470 shares of company stock worth $3,509,414 over the last quarter. 5.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Maze Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Royal Bank of Canada boosted its position in Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after buying an additional 363 shares during the period. Ameritas Investment Partners Inc. increased its position in shares of Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares in the last quarter. California State Teachers Retirement System raised its position in shares of Maze Therapeutics by 138.0% in the 4th quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock valued at $55,000 after purchasing an additional 766 shares during the last quarter. Police & Firemen s Retirement System of New Jersey lifted its stake in shares of Maze Therapeutics by 18.5% during the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 5,961 shares of the company’s stock worth $247,000 after buying an additional 931 shares during the period. Finally, Legal & General Group Plc grew its stake in Maze Therapeutics by 23.0% during the 3rd quarter. Legal & General Group Plc now owns 5,219 shares of the company’s stock valued at $135,000 after purchasing an additional 977 shares during the last quarter.

Analyst Ratings Changes

Several equities research analysts have weighed in on MAZE shares. BTIG Research reaffirmed a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a research note on Wednesday. Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Maze Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $66.00.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.